What is HC Wainwright’s Forecast for EYPT FY2026 Earnings?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) – Investment analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Eyepoint Pharmaceuticals in a note issued to investors on Friday, November 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($3.64) for the year, down from their prior forecast of ($3.40). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($3.46) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q4 2026 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.43) EPS, Q4 2027 earnings at ($0.22) EPS and FY2027 earnings at ($1.56) EPS.

A number of other brokerages have also weighed in on EYPT. Citigroup cut their price target on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Jefferies Financial Group downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research report on Monday, October 19th. Wall Street Zen raised shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 27th. JPMorgan Chase & Co. lowered shares of Eyepoint Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday, October 20th. Finally, Guggenheim cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, October 19th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $21.85.

Read Our Latest Stock Report on EYPT

Eyepoint Pharmaceuticals Stock Performance

NASDAQ EYPT opened at $0.30 on Tuesday. The business has a 50 day simple moving average of $2.24 and a 200 day simple moving average of $10.17. Eyepoint Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $19.11. The stock has a market cap of $25.86 million, a price-to-earnings ratio of -0.08 and a beta of 1.84.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.14). Eyepoint Pharmaceuticals had a negative net margin of 13,281.23% and a negative return on equity of 146.17%. The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.23 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System boosted its position in Eyepoint Pharmaceuticals by 2,158.3% during the 1st quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock worth $1,355,000 after acquiring an additional 100,447 shares during the last quarter. Commodore Capital LP bought a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth approximately $36,414,000. Walleye Capital LLC bought a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth approximately $3,869,000. Swiss National Bank bought a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth approximately $1,900,000. Finally, Stempoint Capital LP raised its holdings in shares of Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after purchasing an additional 456,915 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

About Eyepoint Pharmaceuticals

(Get Free Report)

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.

Featured Articles

Earnings History and Estimates for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.